Introduction
Familial Mediterranean fever (FMF) is a recessively inherited disease, prevalent in the Mediterranean basin but less frequent among Ashkenazi Jews. It is manifested by recurrent bouts of febrile peritonitis, pleuritis, and arthritis. The Mediterranean fever gene, MEFV, responsible for FMF was located on chromosome 16p13.3 and identified in 1997. 1, 2 Five of the 30 MEFV mutations known to date are common founder mutations. 3 Of these, the M694V mutation, frequent among North-African Jews, was singled out as associated with severe clinical manifestations [4] [5] [6] [7] and highly penetrant, while the V726A and E148Q mutations, typifying Ashekanzi FMF patients showed incomplete penetrance. [8] [9] [10] [11] MEFV is predominantly expressed in polymorphonuclear (PMN) cells. 2, 12, 13 These cells accumulate in serous cavities during the inflammatory bouts of FMF. A role was proposed for the native MEFV gene in the downregulation of the PMN-related inflammatory responses, and the mutated gene is implicated in prolonging these responses.
The induction of MEFV mRNA in cultured monocytes by Th1 proinflammatory cytokines, IL-1, IFN-g, and TNF-a 13 suggests that the mutated MEFV may function in a broader spectrum of immune cells and in other inflammatory conditions. Consistent with this estimation is the increased concurrence of FMF and other autoinflammatory diseases such as inflammatory bowel disease, 14 BehBet's disease, 15 and other vasculitides. 16 High incidence of BehBet's disease in FMF may be partially explained by a single MEFV mutation carried by the affected patients. 15 Based on increased frequency of the E148Q mutation in uncharacterized recurrent fever syndromes and in inflammatory arthritis complicated with amyloidosis this mutation was suggested to augment inflammation nonspecifically. 17 Increased coincidence of FMF or MEFV mutations and autoimmune diseases, the later driven by auto-antigen-specific immune reactions, has not been reported. Yet, given the high rate of the founder mutations in the general Semite population, reaching 1 : 5 in Jews [8] [9] [10] [11] the concurrence of patients suffering from an autoimmune disease and carrying a single MEFV mutation is expected to be frequent.
Healthy heterozygotes, who are first-degree relatives of FMF patients, have above normal plasma levels of the acute phase reactant C-reactive protein (CRP) and serum amyloid A (SAA), albeit to a lower extent than FMF patients. 18 An increase in branched glycosylation of alpha-1 acid glycoprotein, another acute phase reactant, was shown as well. 19 The heterozygous state may therefore be expressed with low inflammation, and we hypothesized that when interacting with ongoing autoimmune diseases, such a response may augment the inflammatory response evoked by the primary disease and thereby increase its severity.
We chose to assess the clinical status of the MEFV heterozygotes suffering from relapsing-remitting multiple sclerosis (RR-MS), a central nervous system demyelinating disease with autoimmune etiology, extending our pervious genetic studies on Jewish MS patients. [20] [21] [22] MS patients with an RR course present with transient neurological deficits that completely or partially resolve within few weeks. Whereas 10% may remain disability free even 20 years after the first relapse progressive disability develops in most patients. 23, 24 The accumulation of disability may depend on the degree of inflammation and demyelination and may be a subject to genetic regulation. 21, 25, 26 MS has little in common with FMF, despite the report on MS like white matter brain lesions in three Turkish patients suffering from FMF by Topcouglu et al, 27 and a description of transient optic neuritis in two Israeli FMF patients by Losos et al. 28 The hypothesis that an MEFV mutation may affect the progression of RR-MS is the subject of the present study. We evaluated the association between the MEFV genotype and progression to neurological disability according to established milestones of the expanded disability status scale (EDSS). 23 In recognition that Sephardi and Ashkenazi MS patients diverse in the MS related genetic background 29, 30 these two ethnic cohorts were analyzed separately.
Results
The frequency of MEFV mutations among Jewish MS patients There were 59 non-Ashkenazi (28 North-African Jewish, 31 Iraqi Jewish) and 85 Ashkenazi and in all 144 MS patients in the study group. The non-Ashkenazi cohort included 48 RR and 11 PP patients. The Ashkenazi cohort included 75 RR and 10 primary progressive (PP) patients.
In all 31 patients (21.5%) of the entire study group carried a common MEFV mutation and one (0.7%) had two mutations: V726A and E148Q (Table 1 ). There were no significant differences in the frequency of each of the studied mutations between the MS patients and healthy subjects for any of the tested ethnic populations. The mutation alleles distributed proportionally between the RR and the PP patients (30 vs 3 mutations, respectively, P ¼ 0.7) and between female and male patients (22 mutations among 96 female patients and 10 among 48 males, P ¼ 0.8). As expected, the overall mutation frequency was much lower in MS patients than in the corresponding cohorts of FMF patients ( Table 1 ). All in all, the MEFV mutations were not over-represented in the MS group, suggesting that the susceptibility to develop MS was independent of the MEFV mutation rate.
Association between progression to disability and MEFV mutations in RR-MS patients All 48 non-Ashkenazi RR-MS patients and 71/75 Ashkenazi RR-MS patients had sufficient data to analyze progression of disability. The average disease duration and the mean age at disease onset of MEFV mutation carriers were comparable to those of the noncarriers in each ethnic group ( Table 2 ). The mean yearly attack rate was significantly lower in the heterozygous patients than in the noncarrier patients of the North-African and Iraqi-Jewish (non-Ashkenazi) cohorts, when combined (Table 2) . Despite the lower attack rate (and similar mean disease duration) the proportion of patients who reached EDSS ¼ 3.0 and 6.0 in the non-Ashkenazi MEFV heterozygous group was twice higher than in respective noncarriers ( Table 2 ). The yearly attack rate of Ashkenazi patients carrying an MEFV mutation did not differ significantly from Ashkenazi noncarriers, and the proportion of patients that reached the same EDSS milestones was similar ( Table 2) . The mutation frequency is n/2N, where 2N is the number of MEFV alleles in each cohort and n is the number of alleles carrying a specific mutation. NDFnot determined.
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Regardless of the MEFV mutation status the Iraqi Jewish patients had the shortest median time to reach both EDSS ¼ 3.0 and 6.0. The median time to reach EDSS ¼ 3.0 was 10 years in the Iraqi-Jewish patients vs 24 years, and 22 years in the North-African and AshkenaziJewish patients, respectively (P ¼ 0.0003, Figure 1 ). The median time to reach EDSS ¼ 6.0 was 15 years in the Iraqi-Jewish patients vs 26, and 26 in the NorthAfrican and Ashkenazi groups, respectively (P ¼ 0.0001, Figure 1 ).
When stratified according to the MEFV mutation status, the progression to disability in the MEFV heterozygous patient group was faster than in noncarriers in each non-Ashekenazi cohort. The shorter median time reached significance in the North-African Jewish cohort for both EDSS ¼ 3.0 and 6.0 (2 vs 24 years to reach EDSS ¼ 3.0, P ¼ 0.006, and 6 vs 26 years to reach EDSS 6, P ¼ 0.02, in carriers and noncarriers, respectively). The median time displayed a similar trend in the Iraqi-Jewish cohort (1 vs 10 years to reach EDSS ¼ 3.0, P ¼ 0.2; 6 vs 18 years to reach EDSS ¼ 6, P ¼ 0.06, in carriers and noncarriers, respectively). When combined to include 17 non-Ashkenazi carriers and 31 nonAshkenazi noncarriers, the median time was 2 vs 10 years, respectively, to reach EDSS ¼ 3.0 (P ¼ 0.007), and 6 vs 23 years, respectively, to reach EDSS ¼ 6.0 (P ¼ 0.003, Figure 2 ). There was little effect to the exclusion of patients receiving MS immunotherapy before reaching EDSS ¼ 3.0 or 6.0 on the median progression time. Ashkenazi carrier and noncarrier patients did not differ significantly in their median time to reach both EDSS milestone scores (Table 2) , and immunotherapy, received by 50% of Ashkenazi patients before EDSS ¼ 3, was equally distributed between carrier and noncarrier subgroups (P ¼ 0.5).
Carriers of the M694V mutation experienced the fastest progression across all 58 patients who had deteriorated to EDSS ¼ 3.0 and the 43 patients who had Table 2 Relapse rate and progression to disability in RR-MS patients carrying a common MEFV mutation
Carriers (n=17) Noncarriers (n=31) Probability Carriers (n=12) Non-carriers (n=59) Probability Table 3 ). Their mean time to reach EDSS ¼ 6.0 (3 7 1.7 years, n ¼ 3) was rapid even when analysis was restricted to non-Ashkenazi patients: as a trend when patients carried another mutation (7.4 7 5.3 years, n ¼ 8, P ¼ 0.2), and significantly when patients were noncarriers (12.1 7 10.2 years, n ¼ 11, P ¼ 0.02).
Discussion
In the present study, we examined the association between mutations in the MEFV gene and progression of MS in Israeli Jewish patients. The combined frequency of three founder mutations, M694V, V726A, and E148Q, and of each mutation alone showed no increased frequency in MS patients over ethnically matched unaffected subjects (Table 1) . Mutation carriers were as frequent among RR as among the PP patients, and the 2.2 : 1 female excess in the mutation carriers conformed to the extent of female over-representation in MS and in this study. These analyses indicate no role of MEFV mutations in triggering MS, and no accountability of the mutations for the incidence of MS patients in Israel. The rarity of reports on the coexistence of MS and FMF is further evidence for the independence of MS occurrence from the MEFV mutation status.
Although not increasing the susceptibility to develop MS, the mutations seem to affect the two main disease variables, disability and relapse rate, but only in the non-Asheknazi patients group, and in opposite directions. The increased disability in face of a lower attack (Figure 2 ), contribute to a shortened median time to cumulate a 50% probability to reach the two EDSS scores in the non-Ashkenazi heterozygous patients. Shorter median times were discerned even for the Iraqi-Jewish carriers although this cohort deteriorated fastest of the three ethnic cohorts (Figure 1) . The high prevalence of the M694V mutation accounts in part for the vulnerability of North-African carriers to the effect of an MEFV mutation on disease progression. Mild mutations did account for the rapid deterioration of Iraqi Jewish carriers, yet the same mutations did not display that effect in Ashkenazi carriers, a pattern consistent with their incomplete penetrance. [8] [9] [10] [11] A second, ethnogenetic factor(s) appears to aggravate the MS course in the entire Iraqi-Jewish MS group. This factor could promote the penetrance of mild MEFV mutations in Iraqi Jewish carriers. On the other hand, the expression of the mild mutations may be suppressed in the Ashkenazi-Jewish patients, by gene variants such as the delta 32 CCR5, associated with a mild MS course 26 and reported more frequent among Ashkenazi Jews (14%). 30 A higher frequency of the consensus HLA type II haplotype for MS, DRB1*1501, DQA1*0102, DQB1*0602 in Ashkenazim 29 compared to the Iraqi Jewish cohort (A Achiron, personal communication) further extends the genetic heterogeneity between the two cohorts that may affect the rate of MS progression. 31 In addition to genetic factors, disease activity may be subdued in Ashkenazi carriers owing to timely treatment in response to a high attack rate (even if statistically nonsignificant). It is possible that subtle enhancement of disease activity could be detected in this cohort with screening for more MEFV mutation types 8 and by monitoring for brain lesion burden rather than EDSS.
It is intriguing to suggest a mechanism, by which the mutated MEFV gene could enhance the development of neurological disability. One possible option is that the mutated MEFV, by failing to downregulate the inflammatory response of monocytes 6 and perhaps of activated microglia within the MS brain lesions, may augment the secretion of oligotoxic and neurotoxic compounds. Downstream of the MEFV, along the inflammatory cascade, high SAA levels may chemoattract T cells to the MS lesion. 32, 33 SAA may also directly impede remyelination by inhibiting de novo synthesis of cholesterol, phospholipids, and triglycerides. 34 Demyelinated axons may then become liable to transection, a probable cause of permanent dysfunction. 35 Of note, preliminary data show an association between the heterozygous state and a more severe phenotype in rheumatoid arthritis as well (Rabinovich et al, unpublished data) .
Most of the non-Ashkenazi mutation carriers in our study cohort did not receive MS immunotherapy before reaching EDSS ¼ 3.0, a situation that could attribute to their rapid deterioration. It remains to be seen if early MS drug treatment or daily treatment with colchcine could control inflammatory bouts and temperate the progression of disability in such patients. To conclude, our study demonstrates that a single MEFV mutation can modify the progression of neurological disability in RR-MS patients. This effect may be explained by the interaction between the inflammatory cascade of MEFV and adaptive autoimmune responses, and may occur in a broader range of inflammatory diseases. The efficiency of early anti-inflammatory treatment in withholding MEFVrelated progression to disability is yet to be determined.
Patients and methods
Patients A total of 144 MS patients including 123 RR-MS patients, and 21 PP patients attending the MS Center, Sheba Medical Center, Tel Hashomer, Israel, either of European Jewish (Ashkenazi), Iraqi Jewish, or North-African Jewish, were included in the genetic study. Both the patients' parents were of the same origin; in exception four of the Iraqi-Jewish patients had one Iraqi-Jewish and one Sephardi-Jewish parent (one Syrian, one Turkish and two of Egyptian origin). Of the 144 patients, 141 met the criteria of Poser 36 for definite diagnosis of MS, and three patients met the criteria for probable MS. All patients gave their written, informed consent to blood drawing for the purpose of genetic studies on MS, as approved by the hospital and the Ministry of Health committees.
Control subjects
The frequency of MEFV mutations among MS patients was compared to that in 101 Iraqi Jews, 120 Moroccan Jews and 300 Ashkenazi Jews subjects (whose both parents were of that origin) and who did not suffer from FMF or MS. The enrollment of the subjects and the frequencies of the mutations M694V, V726A, and E148Q obtained are described elsewhere. 10 The mutation frequency among MS patients was also compared to that in 51 Iraqi-Jewish, 60 North-African Jewish, and 22 Ashkenazi FMF patients attending the FMF clinic at our hospital. Their MEFV genotypes were available from our FMF molecular diagnostic registry.
Clinical history of RR-MS patients
Data were drawn from computerized data files assembled at the MS Center before the MEFV mutation analysis was performed. It included age, sex, age at disease onset, disease duration, relapse rate, the time (in years) to reach EDSS ¼ 3.0 and 6.0, and the period of immunotherapy with IVIG, copaxone, or betainterferons.
Progression to disability
The EDSS 23 is a scale for MS and neurological assessment that integrates eight systems: motor, sensory, cerebellar, brainstem, visual, mental, sphincter, and other. EDSS ¼ 0.0 implies normal function, EDSS ¼ 10.0 implies death from MS. EDSS ¼ 3.0 stands for moderate disability in one functional system or mild disability in three/four functional systems, when the patient is fully ambulatory. EDSS ¼ 6.0 stands for walking with assistance for a distance of 100 m. EDSS scores of patients in this study were determined during remission. Medians of the time to EDSS ¼ 3.0 or 6.0 were derived from Kaplan-Meier survival plots of appropriate patient groups.
Detection of MEFV mutations
The mutation screen included common mutations in Israel and the less common K695R mutation described in the Ashkenazi group. Genomic DNA was prepared from peripheral white blood cells using a commercial kit (High pure PCR template preparation kit, Roche, IN, USA). A segment of exon 2 of the MEFV gene containing the E148Q mutation site and a segment of exon 10, containing the M694V and V726A mutation sites, were PCR-amplified with appropriate primers, and the corresponding mutations were identified by restriction enzyme analysis as previously described. 10 The K695R mutation was detected using a commercial kit (Pronto FMF, Savion, IL, USA).
Statistical analysis
Statistical analysis was performed using the SPSS software for windows (version 9). The differences in frequency of mutations were compared between MS patients and ethnically matched, healthy subjects or FMF patients using the Fisher's exact test. The same test was used to analyze the proportion of RR-MS patients that reached EDSS ¼ 3.0 or 6.0 among MEFV mutation carriers and noncarriers, and for the distribution of patients who received immunotherapy before reaching EDSS ¼ 3.0 or 6.0. The medians of time to reach EDSS ¼ 3.0 or 6.0 were compared between groups by the log rank test. The difference in age at RR-MS onset, disease duration, yearly relapse rate and mean time to reach EDSS ¼ 3.0 and 6.0 between carriers and noncarriers in each ethnic group were analyzed by Student's t-test. Significance was considered when Po0.05.
